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Abstract
Background: Human papillomavirus (HPV)-associated malignancy remain a main cause of cancer in men and
women. Cancer immunotherapy has represented great potential as a new promising cancer therapeutic approach.
Here, we report Mesenchymal stem cells (MSCs) as a carrier for the delivery of oncolytic Newcastle disease virus
(NDV) for the treatment of HPV-associated tumor.
Methods: For this purpose, MSCs obtained from the bone marrow of C57BL mice, then cultured and characterized
subsequently by the flow cytometry analysis for the presence of cell surface markers. In this study, we sought out
to determine the impacts of MSCs loaded with oncolytic NDV on splenic T cell and cytokine immune responses,
caspase-3 and -9 expression, and myeloid and myeloid-derived suppressor cells (MDSCs) by histological and
immunohistochemical studies in the tumor microenvironment (TME).
Results: Our findings proved that MSCs possess both migratory capacity and tumor tropism toward transplanted
tumor tissue after peritumoral administration. Tumor therapy experiments indicated that oncolytic NDV delivered by
MSCs-engineered system significantly reduces tumor growth, which is associated with the enhancement of E7-
specific lymphocyte proliferation, CD8+ T cell cytolysis responses, and splenic IFN-γ, IL-4 and IL-12 responses
compared with control groups. Moreover, the treatment upregulated the concentration of apoptotic proteins
(caspase 9) and increased infiltration of tumor microenvironment with CD11b +myeloid and Gr1 + MDSCs cells.
Conclusions: Our data suggest MSCs carrying oncolytic NDV as a potentially effective strategy for cancer
immunotherapy through inducing splenic Th1 immune responses and apoptosis in the tumor microenvironment.
Keywords: Mesenchymal stem cells, Oncolytic Newcastle disease virus, Human papillomavirus, CD8 + , Tumor
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Background
Human papillomavirus (HPV) is one of the most usual
reproductive tract viral infection that accounts for ap-
proximately 90% of cervical and anal carcinomas and
also 60% of oropharyngeal cancer [1]. Human papilloma-
virus (HPV) 16 and 18 are two types of high-risk HPV
associated with most malignancy. The growth of HPV-
associated cancers depends on the continued expression
of the viral E6 and E7 oncogenes [2]. In spite of ad-
vances in diagnostic methods, these types of cancer are
reported to cause 640,000 new cases annually in both
sexes [3]. Thus, developing novel therapeutic approaches
is urgently in demand [4, 5].
Cancer cells with high replicative activity, their defi-
ciencies in antiviral type I interferon signaling, and cell
surface overexpression of receptors-mediated cellular
entry of virus [6], all provide the opportunity to employ
oncolytic viruses (OVs) as a novel tool for cancer ther-
apy. OVs can selectively infect and kill tumor cells while
leaving normal cells intact [7].
The principal systemic anti-tumor mechanism of onco-
lytic viruses is likely based on the virally induction of im-
mune response to identify and present tumor antigens.
Oncolytic virus replication within tumor cells attracts im-
mune cells into the tumor microenvironment, leading to
cross-priming of tumor-associated antigens (TAAs) for
triggering the effective antitumor immunity [8, 9].
Newcastle disease virus (NDV) is an RNA virus be-
longing to the paramyxovirus family and has been
known to induce apoptotic cell death in malignant cell
lines [10]. As an oncolytic virus, NDV is a potential tool
for cancer therapy and has proved to be a safe and ef-
fective antitumor agent [11].
It has been shown that the NDV prevails the immunosup-
pressive micro-environment of tumors and can directly lead
to promoted immune responses due to the increased pro-
duction of cytokines, particularly interferon (IFN) and the
immunogenic cancer cell death (ICD) [12].
One of the major obstacles in the use of naked viruses in
cancer virotherapy is the host immune system, which re-
duces the effectiveness of treatment through complement-
mediated antibody-dependent neutralization [13].
To protect the oncolytic virus from the adverse effects
of immune-mediated clearance or neutralization, using
cell carriers have been proposed as a novel approach
[13, 14]. In addition, the use of cells with intrinsic cap-
ability to migrate within the tumor microenvironment
for delivery of anti-cancer agents increases the effective-
ness of treatment [15]. Previous studies have evaluated
several candidates of carrier cells, including monocytic
cells, dendritic cells, mesenchymal stem cells (MSCs),
and tumor cells [16]. MSCs represent the characteristics
of a promising delivery vehicle that protect the oncolytic
viruses from the effects of complement-mediated
neutralizing antibodies [12], and also possess the unique
ability to steer them toward inflammation and tumor
growth sites [14].
The use of MSCs to deliver the oncolytic measles virus
is underway in phase I/II clinical trial (NCT02068794).
It has been demonstrated that by employment of the
carrier cell, the virus particles escape detection by the
circulatory system and evade the immune system. Fur-
thermore, due to the tumor-homing abilities and also
their suitability for virus replication, these delivery vehi-
cles can be used for therapeutic purposes [15]. Consider-
ing these, we aimed at assessing the in vivo efficiency of
cancer immunotherapy on a syngeneic murine papillo-
mavirus cancer model using MSCs loaded with NDV.
Methods
Virus and cell lines
The LaSota NDV strain used in this study was prepared
from Razi Institute of Serum and Vaccine Research Cen-
ter. The strain was propagated in the allantoic cavity of 9-
to 11-day-old SPF embryonated chicken eggs, and all al-
lantoic fluid samples were harvested and kept at − 80 °C
until use. The titer of the virus was determined using Em-
bryo Infectious Dose 50 (EID50). In order to inactivate
NDV, the sample was exposed to the UV radiation [17]
and the result was confirmed by Vero cell line [18, 19].
The finding revealed that the UV-inactivated NDV does
not create any plaques in Vero cells. EID50 is commonly
used as a titration unit of the NDV. For EID50 to PFU
conversion, we used EID/50 ∼ 0.7 PFU formula [20].
The murine TC-1 cell line was purchased from the
National Cell Bank of Iran (Pasteur Institute of Iran).
Briefly, TC-1 cells were cultured in complete RPMI 1640
media (Gibco BRL, Gaithersburg, MD, USA) containing
10% fetal bovine serum (FBS) (Gibco, Rockville, MD),
100 U/mL of penicillin, 100 μg/mL of streptomycin and
0.4 mg/mL G418 (all from GIBCO, UK), 0.5 mM sodium
pyruvate (Sigma Aldrich, Germany), and 2 mML-glu-
tamine. The EL4 cell line (murine T-cell lymphoma of
haplotype H-2b derived from C57BL/6 mice) was cul-
tured in RPMI 1640 supplemented with 10% FBS. In
addition, MSC cells were flushed from the femurs and
tibia of female 6–8-week-old C57BL/6 mice and seeded
onto a petri dish containing MSC DMEM F-12 medium
(Gibco, UK), 10% FBS, and 100 U/mL of penicillin, 100
μg/mL of streptomycin. The cells were grown for 2–3
weeks until almost confluent. Adherent cells were then
detached by 0.25% trypsin-EDTA and replated using a 1:
3 dilution until the third passage. All the cells were incu-
bated at 37∘C in a humidified 5% CO2 incubator.
Mice
Six- to 8-week-old female C57BL/6 (H2b) mice were
purchased from the Institute Pasture of Iran (Tehran,
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Iran). The mice were adapted to the environment for 1
week before the experiment, and had free access to food
and water and were kept in a 12–12 light period. All ex-
periments were performed according to the Ethical
Committee for the use and care of laboratory animals of
Iran University of Medical Sciences (ethics number:
IR.IUMS.FMD.REC 1396.9321540001).
Flow cytometry analysis
To verify the stromal nature of cultured cells, the expressions
of surface antigens CD44 and CD105 as MSCs markers and
antigens CD45 and CD34 as hematopoietic cell markers with
proper control isotypes and flow cytometry (BD FACS ARIA
II, Becton Dickinson, San Jose, CA, USA) were assessed fol-
lowing fluorochrome-conjugated monoclonal antibodies, in-
cluding fluorescein isothiocyanate (FITC)-labeled anti-CD44
(Cat. No. 561859) and -CD105 (Cat. No. 565944) (50 μg/ml),
and phycoerythrin (PE)-labeled anti-CD45 (Cat. No. 561087)
and -CD34 (Cat. No. 551387) (25 μg/ml) (all from BD Biosci-
ences, USA). Briefly, cultured cells were trypsinized with
2.5% trypsin-EDTA, washed twice with PBS, and incubated
with 10 μl of mentioned antibodies at room temperature for
30min in the dark. Permeabilization with 0.1% Triton X-
100/PBS for 1min was performed before incubation with the
intracellular markers. The cell populations were then charac-
terized according to the surface markers using a FACS Cali-
bur flow cytometer (BD Bioscience, USA). The data were
collected and analyzed using Flowjo software (Version 7.6).
In addition, nonspecifically labeled proteins were identified
by suitable isotype-matched antibodies.
In vitro osteogenic and adipogenic differentiation
potential of MSC
Bone marrow MSCs (BM-MSCs) at third passage had
been cultured in 12-well cell culture plate (SPL Inc.,
Korea) until approximately 90% confluence before adi-
pogenic and osteogenic differentiation media were added
as previously described [21]. Adipogenic differentiation
medium was made with DMEM supplemented with
10 μg/ml insulin and 10− 6 M dexamethasone (all supple-
ments from Sigma, St Louis, MO). Adipogenesis was
confirmed after 21 days by Oil Red O (Sigma-Aldrich)
staining and the accumulation of neutral lipids in fat
vacuoles.
Osteogenic differentiation medium was made with
DMEM supplemented with 10− 8 M dexamethasone,
10 mM β-glycerophosphate, and 50 μg/ml ascorbic
acid (all supplements from Sigma, St Louis, MO). The
media was changed twice a week for 3 weeks. Matrix
mineralization was confirmed by calcium phosphate
deposits after staining with 0.2% Alizarin Red S (2%
aqueous solution, pH 4.1–4.3, adjusted with ammo-
nium hydroxide) for 20 min.
Viral infection of BM-MSCs with oncolytic NDV
The isolated MSCs were cultured in a six-well plate at a
cell density of 5 × 105 cells/well for 24 h. To determine
the packaging efficiency of the MSCs, the MSCs were in-
fected with the various multiplicity of infection (MOI)
(1–40) of NDV for 1 h in DMEM F-12 medium. After-
ward, NDV-encapsulated MSCs were washed with PBS
for removal of the NDV from the supernatant medium.
The cytotoxic effects of the different NDV MOIs on
MSCs was evaluated by Cell viability assay (MTT)
(sigma, USA) [22, 23].
In vivo tumor treatment experiment
In vivo tumor induction was conducted through
subcutaneous (s.c.) injection of 7 × 105 TC-1 tumor
cells/mouse into the right flank area of the mice on day
0, then they randomly divided into six different groups
(10 mice/group). Ten days after tumor cells injection,
C57BL/6 mice were treated peritumorally (p.t.) with
MSC (105 cell/100 μl), MSC/iNDV (105 cell/100 μl con-
taining inactivated NDV), MSC/NDV (105 cell/100 μl
containing activated NDV), iNDV (108 PFU/100 μl inac-
tivated NDV), NDV (108 PFU/100 μl activated NDV)
and PBS (100 μl) twice at 1 week intervals. Tumor
growth and survival were monitored two to three times
a week. Thereafter, mice were monitored twice a week
by inspection and palpation. Tumor size was monitored
by measuring the length (i.e., the longest dimension) and
width (i.e., the shortest dimension) using electronic cali-
pers. Tumor volume was calculated by the following for-
mula: tumor volume = 0.5 × (length + width2).
BM-MSC transduction and GFP reporter gene detection
BM-MSCs were transduced with a lentiviral vector ex-
pressing the enhanced green fluorescent protein (eGFP)
gene (a gift from Stem Cell Technology Research Center,
Tehran, Iran) at a multiplicity of infection of 10 (MOI =
10) and the transduction efficiency was evaluated dir-
ectly in cell culture using fluorescence microscopy
(Olympus, Tokyo, Japan) after 24 h (Fig. 2).
In order to track the migration and distribution of
injected BM-MSCs transduced with eGFP (MSC-eGFP)
in the tumor microenvironment, 105 MSCs at the third
passage in 100 μL of PBS were injected into tumor-
bearing mice through the peritumoral administration
procedure. Mice (n = 3/group) were sacrificed under
deep anesthesia after the injection, and the intensity of
fluorescent signal was evaluated in tumor sections.
Lymphocyte proliferation assay (LPA)
In order to investigate whether treatment with the mes-
enchymal stem cells infected with oncolytic NDV could
induce antigen-specific cell-mediated immunity, lympho-
cyte proliferation was performed in vitro. In this assay,
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the capability of re-stimulated splenocytes in converting
tetrazolium to insoluble purple formazan was evaluated.
One week after last treatment, splenocyte culture at 2 ×
105 cells/well was established in 96-well round-bottom
plates containing RPMI-1640 supplemented with 10%
FBS, 1% L-glutamine, 1% HEPES, and 0.1% penicillin/
streptomycin (in triplicate), followed by 72 h incubation
at 37 °C in a 5% CO2 incubator in the presence of 1 μg/
ml E7-specific H-2Db CTL epitope (1 μg/ml, Biomatik,
Ontario, Canada, > 99% purity), PHA (positive control),
and medium alone as negative control. Afterward, the
supernatants were removed, and the pellets were solubi-
lized in 100 μl dimethyl sulfoxide attempting to elimin-
ate the possibly produced crystals of formazan. Plates
were read at a wavelength of 540 nm and stimulation
index was used for expressing the results. This index
was obtained as follows:
stimulation index
¼
OD values of stimulated cells Csð Þ
−relative cell numbers of unstimulated cells Cuð Þ
relative OD values of unstimulated cells
In vitro cytotoxic activity
To confirm whether mesenchymal stem cells infected
with oncolytic NDV could induce cytotoxic immune re-
sponses by activating antigen-specific cytotoxic T lym-
phocytes, in vivo cytotoxic T lymphocyte (CTL) assay
was performed by the measurement of lactate dehydro-
genase (LDH) release. One week after the last treatment,
a single-cell suspension of splenocytes was prepared and
applied as effector cells. For the preparation of the target
cells, EL4 cells were pulsed with 1 μg/ml E7-specific H-
2Db CTL epitope. An exact viable number of 4 × 104
EL4 cells in a volume of 100 μl (as target cells) were co-
cultured with effector cells (100 μl) at 50:1 effector-to-
target cell (E/T) ratios, in which a maximal release of
LDH was observed. After centrifugation, the superna-
tants (50 μl/well) were transferred to 96-well plates, and
CTL activity was measured [24].
Cytokine ELISA assay
Seven days after the second treatment, the spleen of the
mice (n = 3) were isolated and mononuclear cells from
spleen of immunized mice were seeded at a concentra-
tion of 2 × 105 cells/well in 24-well plates (TPP,
Switzerland) for 3 days in RPMI1640 supplemented with
10% FBS, 1% L-glutamine, 1% HEPES, 2.5 mM 2-
mercaptoethanol, and stimulated with E7-specific H-
2Db CTL epitope at a concentration of 1 μg/ml (Bioma-
tik, Ontario, Canada, > 99% purity) at 37 °C in 5% CO2.
The cell supernatants were collected after 48 h and the
secretion of IL-4, IFN-γ and IL-12 in the supernatant
were evaluated by commercially available ELISA kits
(R&D Systems Inc., Minneapolis, Minn, USA) following
the manufacturer’s instructions. All samples were per-
formed in triplicate and the plates were read at optical
density (OD) 450 nm.
Intratumoral activity assay of Caspase 3 and Caspase 9
Intrinsic apoptosis is one of the pathways that may be
induced by oncolytic NDV. Caspase-3 and -9 activities
in the tumor microenvironment were measured by cas-
pase ELISA kit (Abcam, Cambridge, MA, USA). Briefly,
the tumor tissue was extracted from each group (n = 3)
and 100 mg of discarded tissue homogenized in 0.5 ml
lysis buffer (0.1 M Tris-HCl (pH 7.6) and 0.1 M fresh di-
thiothreitol). After centrifugation at 10,000×g (1 min),
equal amount of supernatant was added to the
substrate-containing reaction buffer (0.1 M dithiothreitol
and 5 μl of 4 mM DEVD-p-NA) and incubated for 120
min at 37 °C. Finally, the caspase-9 and -3 activities were
assessed by the microplate reader (BioTek, 800TS, USA)
at an absorbance of 405 nm. Each experiment was re-
peated in triplicate.
Histology and immunohistochemistry (IHC)
For histological analysis, harvested tumor tissues were
collected and immersed in 10% buffered formalin and
then embedded in paraffin. Specimens were sectioned at
5 μm thickness and stained with hematoxylin/eosin
(H&E). Finally, all specimens were observed under
microscope (Nikon) and images were captured with
digital camera (RT color SPOT). Subsequently, mitotic
cells and histological structure between different groups
were compared.
To evaluate the level of myeloid and myeloid-derived
suppressor cells (MDSCs) in tumor tissue, the tumor sec-
tions were also analyzed immunohistochemically using
anti CD11b (BioLegend Cat. No. 101207) and anti-Gr-1
(BioLegend Cat. No. 108407) antibodies, respectively.
Briefly, Tumor tissue sections were deparaffinized and
rehydrated in alcohol gradients and then washed and
boiled for antigen retrieval (10 min at 95 °C). In the next
step, sections were blocked using bovine serum albumin
(BSA) and incubated with biotinylated goat anti-rat sec-
ondary antibody (1:500, Sigma Aldrich) for 1 h at room
temperature. After washing and incubation with horse-
radish peroxidase (HRP)-conjugated streptavidin (Sigma-
Aldrich, Pro. No. 18–152), the reaction was revealed
with DAB (Sigma-Aldrich). Cell counting was performed
on randomly taken photographs of IHC-stained sections
from four independent samples, using an oil-immersion
100x objective. Finally, image J software (NIH, Bethesda,
USA) was used to quantify stained regions.
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Statistical analysis
All statistical analysis was performed using the SPSS
16.0 software through one-way ANOVA technique. A
value of *P < 0.05, **P < 0.01 and ***P < 0.001 were con-
sidered to demonstrate statistical significance.
Results
MSC characterization and cytotoxicity assay
The proliferation of the bone marrow-derived mesen-
chymal stem cells of female mice femur as a hallmark of
MSCs, was demonstrated through identification of
Osteogenic and adipogenic differentiation of MSCs using
Alizarin Red and Oil Red O staining, respectively (Fig. 1a,
b). These findings indicated that obtained cells were able
to differentiate into osteogenic (calcium phosphate de-
position) and adipogenic (lipid granules accumulation)
cells. Furthermore, flow cytometric analysis was per-
formed on cultured cells at the third passage to
characterize the purity of MSCs using markers com-
monly used to characterize mouse mesenchymal cell
surface markers, namely, CD45, CD34, CD105, and
CD44 antibodies. The analyses showed that the majority
of BM-MSCs expressed high levels of CD44 (94.8%) and
CD105 (91.7%) cell surface markers. Although, the ma-
jority of BM-MSCs were negative for CD45 (99.4%), a
hematopoietic cell surface marker; and CD34 (99.8%)
(Fig. 1c). This observation was consistent with the gen-
eral description of the phenotypic profile of classical
MSCs. In this regard, cytotoxicity results indicated that
MOIs 1–20 induced only a small degree of cell death
when compared with control group, although this rela-
tionship was not significant (p > 0.05). In contrast, we
found that infection of the MSCs with 40 MOI of NDV
induced significant cell death after 72 h (around 20%)
(Fig. 1d). Based on the results, the MOI of 20 was
chosen as an optimum dose for BM-MSCs infection.
The data reported are representative of three independ-
ent experiments, each performed in duplicates.
In vivo tracking of MSCs in tumor microenvironment by
immunofluorescence microscopy
We investigated the tropism of MSCs to tumors in a
HPV16 E6/E7+ syngeneic TC-1 mouse tumor model.
For this regard, mouse MSCs transfected with lentiviral
vectors expressing eGFP for the purpose of tracking mi-
gration. Transduced MSCs were administrated into
tumor-bearing mice through the peritumoral route, and
MSC localization was evaluated by fluorescent micros-
copy (Fig. 2). Our results confirmed the migratory cap-
acity of MSCs toward TC-1 tumor after peritumoral
delivery which could be detected in tumor sections on
day 4 (Fig. 2-C).
NDV-loaded MSC and NDV groups enhanced the
stimulation of T lymphocytes proliferation and cytotoxic
effect
To determine whether the E7-specific lymphoprolifera-
tive response mainly resulted from a response to the
BM-MSCs transduced with oncolytic NDV, Lympho-
cyte proliferation assay was performed in experimental
groups. As previously mentioned, our treatment groups
including MSC, MSC/iNDV, MSC/NDV, iNDV, NDV
and PBS were treated peritumoral in two times at
seven-day intervals. The mice treated with MSC/NDV
and NDV showed a significant lymphocyte proliferation
response when compared with the MSC/iNDV and
iNDV groups (P < 0.001). Moreover, there was no sig-
nificant difference between MSC/NDV and NDV
groups (P > 0.05). Of note, a significant difference was
observed between the MSC/iNDV and iNDV groups in
comparison to the MSC and PBS control groups (P <
0.05). Additionally, there was no expansion of spleno-
cytes against E7 antigen from C57BL/6 mice treated
with MSC and PBS control groups (P > 0.05) (Fig. 3a).
These results suggest that treatment with MSC/NDV
and NDV can significantly stimulate E7-specific T-cell
response. To gain more insight into the anti-tumor
mechanism of the MSCs carrying oncolytic NDV, we
designed an LDH release assay to assess the cytotoxic
activities of the CTLs induced by HPV-16 E7 epitope.
Since the highest percentage of specific target lysis was
detected for E7-specific CTLs at an Effector:Target
(EL4) ratio of 100:1, this ratio has been selected for fur-
ther analysis. Our findings (Fig. 3b) illustrated that
treated mice with MSC/NDV and NDV groups can sig-
nificantly induce higher antigen-specific CTL responses
compared to MSC and PBS groups (P < 0.001). More-
over, a significantly higher E7-specific lytic activity was
detected in mice treated with MSC/NDV, as compared
to mice treated with NDV(p < 0.05) (Fig.3b). As ex-
pected, no antigen-specific cytolytic response was ob-
served for the C57BL/6 mice groups that had been
treated with MSCs and PBS (P > 0.05). Finally, the re-
sult revealed that MSC/NDV and NDV groups could
enhance the specific cytolytic responses against TC-1 in
the syngeneic model.
Oncolytic NDV-loaded MSCs induced anti-tumoral
cytokine secretion
Cytokine assay was employed to monitor the balance
of the cellular immunity induced by MSCs carrying
oncolytic NDV. As shown in Fig. 4 A, C, splenocytes
from the MSC/NDV and NDV-treated mice induced
a significant response of IFN-γ and IL-12 (p < 0.001)
compared to PBS, MSC/iNDV, iNDV, and MSC
groups. The production of these cytokines following
the MSC/NDV treatment was significantly higher than
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in mice that received the NDV alone (P < 0.001). IL-4
levels were significantly increased when the MSC/
NDV was administered compared to PBS, NDV,
iNDV, MSC/iNDV and MSC groups (P < 0.01) (Fig.
4b). These results suggested that the MSCs carrying
oncolytic NDV could induce the Th1 cytokines that
may play a critical role in strengthening the anti-
tumor cellular immune system.
Fig. 1 Differentiation and characterization of bone marrow mesenchymal stem cells (BM-MSCs). MSCs were isolated from the bone marrow of 6-
8 week-old C57BL/6 mice by selective adherence to the plastic cell culture dishes. a Adipogenic (see black arrow) and b osteogenic (see white
arrow) differentiation were evaluated by Oil Red O staining and Alizarin Red as described in the materials and methods. c Flow cytometry
quantification of MSCs after isolation and enrichment showed the MSCs were positive for CD44 and CD105 but negative for CD34 and CD45
markers. d The cytotoxic effects of the different NDV MOIs on MSCs was evaluated by MTT assay at 72 h post-infection. Means are from 3
independent experiments and *(P < 0.05) indicates statistically significant difference between MOI 40 compared with control group
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Screening of CD11b and gr-1 expression and histology
alteration in tumor sections
The evaluation of the myeloid and myeloid-derived sup-
pressor cells (MDSCs) was determined by the expression
of CD11b + and Gr1+ markers using immunohistochem-
istry. We observed that treatment with MSC/NDV and
NDV increased the level of CD11b + cell marker com-
pared to MSC and PBS control groups (p < 0.001). More-
over, results demonstrated that the level of CD11b +
marker was significant in MSC/iNDV compared to MSC
and PBS control groups (p < 0.01). Also, the level of
Gr1+ cell markers increased in MSC/NDV and NDV
group compare to MSC and PBS control (p < 0.001).
Furthermore, the level of Gr1+ increased in MSC/iNDV
compared to the PBS control group (p < 0.01). Immuno-
histochemistry results indicate that treatment with
MSC/NDV, NDV, and MSC/iNDV groups can induce
CD11b myeloid cells which leads to an increase in the
accumulation of pro-inflammatory macrophage in tumor
tissue. Moreover, these treatment groups can augment
MDSCs in tumor microenvironments which can be re-
sponsible for inhibitory effects on immune system cells.
Fig. 2 In vitro and in vivo immunofluorescence visualization of BM-MSCs. a-b Fluorescence microscopy of BM-MSCs transduced with lentivirus
particles in vitro (40× magnification) c Fluorescence microscopy of BM-MSCs transduced with lentivirus particles in tumor tissue (40× magnification),
d Fluorescence microscopy of non- transduced MSC
Fig. 3 Lymphocyte proliferation assay and cytotoxic T lymphocyte response following treatment with MSCs loaded with oncolytic NDV. a The
results indicate that MSC/NDV and NDV groups stimulate significant differences when compared with MSC/iNDV, iNDV (P < 0.001), PBS and MSC
control groups (P < 0.001). Also, the stimulation index was significant in MSC/iNDV and iNDV treated groups compared to MSC and PBS control
groups (P < 0.05). b Results reveal that treatment with MSC/NDV and NDV groups can significantly increase CTL responses compared with control
groups (MSC and PBS groups) (P < 0.001). Also, cytolytic analysis of CTL lymphocytes demonstrated a greatly increased CD8+ activity in the group
of mice treated with MSC/NDV compared with the NDV group (p < 0.05). The results are representative of three independent experiments. * P <
0.05; ** P < 0.01; *** P < 0.001
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To illustrate the efficacy of oncolytic NDV, portions of
syngeneic tumor tissue were sectioned and stained with
H&E on day 7, then examined for characterization of
histological differences between various treated groups.
As shown in Fig. 5, H&E staining disclosed that MSC/
NDV and NDV treated groups has been able to reduce
the amount of proliferation of tumor cells and induced
early signs of necrosis when compared to other groups
particularly MSC and PBS ones.
Oncolytic NDV induces apoptosis in vivo model
OVs directly induce a cytolytic effect on tumor cells or
indirectly promote tumor cells apoptosis [25]. Our previ-
ous studies have shown that oncolytic NDV induces
apoptosis in TC-1 cell line [26]. In addition, Kumar et al.
found that NDV mediates tumor cell killing through
promoting the TNF-related apoptosis-inducing ligand
(TRAIL)/TRAIL-R signaling, caspases activation, as well
as apoptosis in the extrinsic pathway in HeLa cells [25].
In this regard, we investigated the effects of oncolytic
NDV on the activation of caspases-9 and -3 in in vivo
model. To evaluate effects of NDV treatment on tumor
protection could be correlated with the tumor micro-
environment factors, the expression level of caspase pro-
teins 3 and 9 were ascertained in tumor lysates by
ELISA method. We observed that oncolytic NDV in-
duced the activation of caspase-9 in both MSC/NDV
and NDV groups compared to the PBS control group
(p < 0.05). Moreover, regarding the caspase-3 expression,
the results showed an increase among the NDV group
compared to PBS control group (p < 0.05), although no
significant increase was observed in caspase-3 level in
the MSC/NDV group compared to control (p > 0.05). In
the same way, no significant difference was observed in
each of caspases in tumor lysate of MSC/iNDV and
iNDV groups compare to PBS control group (p > 0.05)
(Fig. 6).
Taken together, our results indicate that the use of
oncolytic NDV both in the carrier cell and NDV alone
could potentially induce apoptosis through the internal
pathway. However, no significant changes were observed
in the levels of caspase-3 in MSC/NDV in comparison
with control groups (PBS and MSC) that may be due to
the occurrence of non-apoptotic pathway rather than
apoptosis one, since sometimes viral infection leads to
activation of other programmed cell death such as
necroptosis in a caspase-8-dependent pathway.
NDV-loaded MSCs inhibits tumor growth
Based on immunological (i.e., enhanced CTL prolifera-
tion and cytokines production) and histopathological
effects (enhanced apoptotic activity and MDSCs popula-
tion) (Figs. 3, 4, 5 and 6), we expected that these findings
could be correlated with the inhibitory action on the
Fig. 4 Determination of the splenic IFN-γ, IL-4, and IL-12 cytokine
secretion. Two weeks after last treatment, the spleen was removed in
each group(n= 3), seeded in 96 well plate and re-stimulated with 1 μg/
ml E7-specific epitope. After 48 h, collected supernatants were assayed
for the presence of IFN-γ, Il-4, and IL-12 to investigate the balance of the
immune response. The level of cytokines was measured by comparison
to a standard curve of serially diluted positive control samples. The data
is represented as mean ± S.D. Each sample was examined in triplicate
and results are representative of two experiments. * P< 0.05; ** P< 0.01;
*** P< 0.001
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Fig. 5 Histological and immunohistochemical variations following treatment of syngeneic TC-1 tumor model with oncolytic NDV. a At two weeks
following final treatments, mice were sacrificed and sections of paraffin embedded or frozen tumor tissue from each group were stained with
hematoxylin and eosin (H&E) for evaluation of tumor cells proliferation and signs of necrosis. Moreover, immunohistochemistry (IHC) staining was
done for screening CD11b + and Gr-1+ markers. H&E, × 100 magnification, and IHC, × 40 magnification. Scale bars, 100 μm b The expression level
of Gr-1+ in tumor sections of treatment groups. c The expression level of CD11b + in tumor sections of treatment groups. Immunohistochemical
analysis was performed by ImageJ software. Data are expressed as means ± SEM (b and c). n = 3 mice per group (b and c). * P < 0.05; ** P < 0.01;
*** P < 0.001
Fig. 6 The expression level of caspase-3/9 proteins in tumor lysate of treated groups. Treatment with oncolytic NDV significantly (*P < 0.05)
increased the level of Caspase-9 in NDV and MSC/NDV groups compared to control groups (PBS and MSC). Also, treatments with oncolytic NDV
significantly (p < 0.05) increase the Caspase-3 in NDV group compared to control groups (PBS and MSC). No significant changes were observed in
the levels of caspase-3 in MSC/NDV compare to control groups (PBS and MSC) (p > 0.05)
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tumor growth and regression. Ten days following tumor
cell injection, mice were randomly separated into six
groups and treated two time with NDV-loaded MSCs
(infected with 20 MOI of NDV), same number of iNDV-
loaded MSCs, active NDV (108 PFU) and same dose of
inactive NDV. As a control, we injected the similar num-
ber of MSCs and equal volumes of PBS peritumoraly.
Consequently, mice were examined and the growth of
the tumor was measured by caliper for 6 weeks and the
effect of MSC/NDV on inhibition of tumor growth as
well as reduction of tumor volume was calculated.
As expected, the results proved that in all syngeneic
mouse models treated with MSC/NDV and NDV, the
tumor growth significantly reduced compared to other
groups (Fig. 7). No significant difference was found be-
tween the MSC/NDV and NDV groups (p > 0.05), which
may be due to the anti tumoral effects of MSCs [27].
Cytotoxic effect of bone marrow MSCs on the estab-
lished tumor in a melanoma mouse model through the
release of reactive oxygen species has been presented
[28]. Consistent with these results, studies showed that
secretion of anti-inflammatory mediators by MSCs can
lead to modulation of immune responses [29]. On the
other hand, this immune modulation can be beneficial
for oncolytic activity of NDV.
Moreover, the MSC/iNDV and iNDV groups could
significantly control tumor growth compared to MSC
and PBS control groups (p < 0.01) which approves the
potentials of iNDV to somewhat induce apoptosis and
antitumoral immune responses as shown in Figs. 3 and
6. Compared with the mild anti-tumoral effect of MSC/
iNDV and iNDV groups, active NDV and NDV-loaded
MSCs can remarkably reduce tumor volume by com-
parison with the MSC and PBS control (p < 0.0001).
These results demonstrate that treatment with 108 pfu
active NDV alone or engulfed by MSC (~ 2 × 106 NDV
particles) promotes a strong immune response, which
can turn into an anti-tumor response. Notably, the aver-
age size of the tumor was significantly reduced in MSC/
NDV group compared to MSC/iNDV. In addition, on
week 6, the tumor volumes of TC-1 bearing mice receiv-
ing NDV were significantly smaller than those of mice
receiving iNDV alone. Together, these data confirm the
hypothesis that NDV or iNDV has the potential to re-
duce tumor growth and its anti-tumor activity and the
dose of administration are improved when loaded and
delivered by MSCs as a vehicle. On the other hand, these
findings indicated that the use of MSCs as vehicle has
led to a optimal delivery of viral load in a reduced
dose of administered oncolytic NDV (approximately 2
log). This delivery system would enable the adminis-
tration of a lower viral dose that would reduce side-
effects. These results also indicated that the MSCs
could be used as a suitable carrier for transferring the
NDV to the target site.
Discussion
Oncolytic virotherapy is a novel method for cancer ther-
apy which uses competent replicating viruses to select-
ively eliminate malignant cells [30]. However, efficient
and targeted delivery of the viral-based therapy to the
tumor mass remains a critical clinical challenge. The ap-
plication of MSC as cell carriers for oncolytic viruses
presents a novel and promising approach to overcome
several barriers and augments effector function of onco-
lytic virotherapy in a tumor microenvironment [31]. Sev-
eral studies have assessed the anti-tumoral efficacy of
Fig. 7 In vivo anti-tumoral response experiment in NDV-loaded MSCs mice. Tumor volume was calculated using ocular checkup and palpation
for seven mice per group, three times a week during 6 weeks of monitoring. Error bars represent mean ± SD for each group of mice. ****p <
0.0001 for MSC/NDV and NDV compared to MSC and PBS groups
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mesenchymal stem cells carrying oncolytic viruses for
cancer therapy [31, 32].
To investigate the therapeutic effects of MSCs harbor-
ing the oncolytic Newcastle disease virus (NDV) in the
human papillomavirus-associated tumor, we developed a
syngeneic mouse model of papillomavirus associated
cancer using immunocompetent mice. We demonstrated
that MSCs as a cellular carrier efficiently migrate into
the tumor tissue and deliver therapeutic oncolytic NDV.
In vivo tracking of the MSCs migratory ability in the
tumor microenvironment is essential for the application
of stem cells for cancer immunotherapy.
Furthermore, our studies reveal that the MSCs carry-
ing oncolytic NDV has enhanced antitumor efficacy in
TC-1 tumor mouse model, which is associated with an
increase in antigen-specific lymphocyte proliferation,
CD8+ cytotoxicity, and IFN-γ induction. The results also
indicated that the ability of MSCs carrying oncolytic
NDV to induce a robust antigen-specific cytolytic im-
mune response leads to a strong antitumor activity
against E7-expressing TC-1 tumor murine model, slow-
ing tumor growth in tumor treatment experiments
in vivo. As a result, the application of MSCs carrying
oncolytic NDV has been preferred due to lower undesir-
able systemic toxicity and efficient delivery of reduced
dose of NDV.
Application of oncolytic virus for cancer therapy is
currently being evaluated in clinical trials for different
types of cancers. Among oncolytic viruses explored for
cancer therapy, NDV has demonstrated reasonable safety
profile and selective oncolysis and replication in cancer
cells. In our previous study, we have confirmed the se-
lective antitumor potential of NDV through triggering of
autophagic cell death via ROS induction and activation
of early apoptosis pathways, making it an encouraging
virotherapeutic agent [26]. In addition to direct antitu-
mor effect, oncolytic virotherapy also exerts a robust
danger signal needed for overcoming tumor-induced im-
mune suppression and subsequent stimulation of potent
antitumor immunity in vivo [33].
Oncolytic immunotherapy has been demonstrated to
release a wide range of damage-associated molecular
patterns (DAMPs) and tumor-associated antigens (TAA)
from whole tumor cells using oncolytic virus replication
which would be taken up and cross-presented to CD8+
CTL T cells by activated dendritic cells, consequently
resulting in the activation of a tumor-targeting immune
response [8, 34]. In this regard, Ye et al. reported that
lung cancer cells infected by NDV express a high level of
several DAMPs, including HMGB1, HSP70/90, and
ecto-CRT. The induction of immunogenic cell death
(ICD) by oncolytic NDV can activate immune cells such
as cytotoxic T lymphocytes (CTLs) and also causes the
release of inflammatory responses in tumor model [35].
In support of our findings, previous oncolytic NDV
findings generated from glioblastoma multiforme tumor
in xenotransplant murine models have shown that vir-
otherapy with NDV leads to enhanced infiltration of
IFN-gamma+ CD4+/CD8+ T cells along with a decrease
in myeloid-derived suppressor cells (MDSCs) in the
tumor microenvironment [36].
A growing number of studies point out the importance
of MDSCs in the regulation of immune responses in
cancer and tumor progression. Meanwhile, the diverse
effects of therapeutic agents on MDSC behavior have
been reported [37]. Fend et al. demonstrated that em-
ployment of vaccinia virus armed with suicide gene as a
tool for oncolytic virotherapy increases the infiltration of
tumors by CD3 + CD8+ T lymphocytes and MDSC cells
in tumor lysates of the treated group in an orthotopic
model of renal carcinoma [38]. Moreover, it has been
determined that administration of oncolytic HSV-1
armed with IL-12 in undifferentiated sarcoma model in-
duces higher intra-tumoral CD8:T regulatory cell (Treg)
and CD8:MDSC ratios in treated group [39]. Consist-
ently, our findings demonstrated a pronounced infiltra-
tion of tumors with Gr1+ MDSCs in NDV, NDV/MSC
and iNDV/MSC treated animals in comparison to con-
trols. However, entering our therapy to the tumor envir-
onment may increase the local expansion of immune
cells including granulocytes and monocytes. There is a
possibility of a higher expression of CD11b and Gr-1
surface markers in this experiment, due to their presence
of on granulocytes and monocytes.
The results also agree with recent reports about the
protective properties of CD11b myeloid cells after NDV
virotherapy. Myeloid cells carry out a crucial role in in-
fection and tumor microenvironment. Integrins (such
CD11b) are a family of adhesion receptors that play a
key role in myeloid cells recruitment [40]. Recent studies
have shown the role of CD11b integrin in anti-tumor re-
sponses and inhibition of immune suppression in animal
models and human cancers [40]. Recently, Schmid et al.
demonstrated that activation of CD11b leads to elevated
pro-inflammatory macrophage polarization through in-
duction of microRNA Let7a [41]. We also noticed that
NDV and MSCs carrying oncolytic NDV treatments lead
to the upregulation of caspase-3 and -9 in tumor tissue.
Correspondingly, Chai et al. showed that NDV inhibited
the growth of A549 tumor xenograft through activation
of caspase-3 [42].
One of the main problems for the use of virotherapy
as an anti-tumor agent is to avoid clearance by host anti-
viral antibodies [43]. One of the inherent characteristics
of MSCs is the ability to implant in tumor tissue that is
dependent on multiple cytokine receptors such CXCR4
and matrix metalloproteinase-2 (MMP-2) [44]. For the
first time, Hamada et al. used the carrier cells to protect
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oncolytic viruses from antiviral immune responses. They
demonstrated that adenovirus-loaded MSC can lead to
effective induction of antitumoral CTL and anti-viral ac-
tivity in syngeneic ovarian tumor model [45].
In a recent study, deployment of an oncolytic
adenovirus-loaded menstrual blood-derived mesenchy-
mal stem cells (MenSCs) vehicle enhanced antitumor re-
sponses following T and NK cells activation [46].
Another study has also documented that intratumoral
injections (i.t.) of oncolytic human adenovirus-loaded
mesenchymal stem cells leads to an increase in anti-
tumoral T cells [15], suggesting that MSCs are an at-
tractive vehicle for targeted delivery in oncolytic therapy.
Future investigations should address whether this
method has the potential for translation into the clinical
applications.
Conclusions
To sum up, our results suggest that the MSC carrier
represents a valuable tool for delivery of oncolytic NDV
as it induces an effective specific immune response in-
volving T cell response, slight rise in MDSCs, and elic-
ited significant increase in expression of caspase-9.
Collectively, our findings provide the rationale for the
development of oncolytic NDV-loaded MSC carrier for
enhancement of treatment efficacy in HPV infection and
HPV-associated diseases.
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